3000+ Attendees, 450 Speakers, 12 Conference Tracks, 100+ Posters
 
MMTC15_Header  
MMTC M Header 

Cambridge Healthtech Institute’s Sixth Annual

Personalized Diagnostics

Impacting Care and Improving Outcomes

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference

 

Now that the goal of moving NGS to the clinic has been accomplished, the next step is to ensure proper usage and adoption. Developing standards, protocols, robustness, cost-effectiveness and reimbursement of assays are all of prime importance. This year’s Personalized Diagnostics conference will review recent progress for building an infrastructure to incorporate the use of NGS and circulating biomarkers in the clinic for cancer, prenatal, cardiovascular, pediatric and genetic disease applications and illustrate value-added testing using case studies.


PLENARY KEYNOTE SESSION

PANEL DISCUSSION: Value of Clinical Utility

Moderator: Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP
Panelists to be Announced


CASE STUDIES IN PRENATAL DIAGNOSTICS

History Leading Up to NIPT

Mark I. Evans, M.D., Clinical Professor, Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine, Mount Sinai Hospital

End-User of Prenatal Testing in Clinical Practice

Edward Wolf, M.D., Northwestern University

Case Studies in NIPT

Nicole Teed, Medical Science Liaison, Sequenom, Inc.


CASE STUDIES OF AN INTEGRATED APPROACH TO PATIENT CARE

Case Study: Clinical Exome Sequencing for the Diagnosis of Neurodegenerative Disorders

Rong Mao, M.D., Associate Professor, Pathology, University of Utah; Medical Director, Molecular Genetics, ARUP Laboratories

Case Study: Clinical Utility of Multiple-Gene Sequencing Panels for Hereditary Cancer Risk Assessment

James M. Ford, M.D., Associate Professor, Medicine & Genetics, Division of Oncology, Stanford University School of Medicine

Case Study: Applying Next-Generation Sequencing for Mutation Detection in Hematologic Malignancies with an Emphasis on Value Added To Patient Care

Jennifer J.D. Morrissette, Ph.D., Clinical Director, Center for Personalized Diagnostics, University of Pennsylvania

Case Study: Applying Next-Generation Sequencing for Rapid Pathogen Detection

Charles Chiu, M.D., Ph.D., Assistant Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

Information Innovation for Clinical Implementation of Next-Generation Sequencing

Shelly Gunn, M.D., Ph.D., CMO, MolecularHealth, Inc.
David Jackson, Ph.D., CSO, MolecularHealth, Inc.


TAKING A SNAPSHOT OF BLOOD, PLASMA AND SERUM TO LEARN ABOUT THE HEALTH OF THE PATIENT

Translating a Trillion Points of Data into Therapies, Diagnostics, and New Insights into Disease

Atul Butte, M.D., Ph.D., Division Chief and Associate Professor, Stanford University School of Medicine; Director, Center for Pediatric Bioinformatics, Lucile Packard Children’s Hospital; Co-founder, Personalis and NuMedii

Adventitious Maternal Cancer Detection during Non-Invasive Prenatal Testing of Circulating Fetal DNA

Juan-Sebastian Saldivar, M.D., FACMG, Vice President, Clinical Services and Medical Affairs, Sequenom Laboratories

Personalized Genomic Analyses of Human Cancer

Victor Velculescu, M.D., Ph.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Cancer Center

Innovative Targeted RNA-Seq Method for Identifying Known and Novel Gene Fusion Events in Tumor Cells

Jonathan Scolnick, Ph.D., Scientist, Research, NuGEN Technologies

Sponsored Presentation


STRATEGIC ISSUES IN NGS-ENABLED CANCER CARE

Advancing Clinical Outcomes with Targeted Therapies for Patients with Solid Tumors Using the Next-Generation Sequencing Assay

Jeffrey S. Ross, M.D., Medical Director, Foundation Medicine, Inc.

The NGS Cost Equation in Cancer Care: Are We at the Tipping Point?

German Pihan, M.D., Director, Hematopathology Lab, Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School


WHAT IS NEEDED FOR TRANSLATION IN THE CLINICAL SETTING?

KEYNOTE PRESENTATION: Common Uses of NGS in the Clinic: Cancer, NIPT and Pediatric Applications

Paul R. Billings, M.D., Ph.D., Individual Consultant 

Sequencing Technology

Dietrich A. Stephan, Ph.D., Chairman, Human Genetics, University of Pittsburgh; Associate Director; Population Genetics and Translational Acceleration, Institute for Personalized Medicine of UPMC & University of Pittsburgh Health

Clinical Delivery

Robert C. Green, M.D., MPH, Director, G2P Research Program; Associate Director, Research, Partners Center for Personalized Genetic Medicine, Division of Genetics, of Medicine, Brigham and Women’s Hospital and Harvard Medical School


TRANSLATING DATA TO PATIENT CARE

KEYNOTE PRESENTATION: Cancer Genomics

David Haussler, Ph.D., Distinguished Professor and Director, Center for Biomolecular Science & Engineering, University of California Santa Cruz

Ranking Omics Data to Discover Diagnostic Biomarkers

Corrado Priami, Ph.D., Computer Science, The Microsoft Research - University of Trento Center for Computational and Systems Biology (COSBI)



For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
T: 781-972-5464
E: clingham@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com
 

 


  2015 Plenary Sessions 


2015 MMTC Prelim Agenda 

Premier Sponsors:

 

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex